Strategies for increasing pancreatic tumor immunogenicity

Research output: Contribution to journalReview articlepeer-review

Abstract

Immunotherapy has changed the standard of care for multiple deadly cancers, including lung, head and neck, gastric, and some colorectal cancers. However, single-agent immunotherapy has had little effect in pancreatic ductal adenocarcinoma (PDAC). Increasing evidence suggests that the PDAC microenvironment is comprised of an intricate network of signals between immune cells, PDAC cells, and stroma, resulting in an immunosuppressive environment resistant to single-agent immunotherapies. In this review, we discuss differences between immunotherapy-sensitive cancers and PDAC, the complex interactions between PDAC stroma and suppressive tumor-infiltrating cells that facilitate PDAC development and progression, the immunologic targets within these complex networks that are druggable, and data supporting combination drug approaches that modulate multiple PDAC signals, which should lead to improved clinical outcomes.

Original languageEnglish (US)
Pages (from-to)1656-1669
Number of pages14
JournalClinical Cancer Research
Volume23
Issue number7
DOIs
StatePublished - Apr 1 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Strategies for increasing pancreatic tumor immunogenicity'. Together they form a unique fingerprint.

Cite this